In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 5, 2005, Pages 415-426

  Gurley, Bill J ^a   Gardner, Stephanie F ^b   Hubbard, Martha A ^b   Williams, D Keith ^b   Gentry, W Brooks ^b   Khan, Ikhlas A ^b   Shah, Amit ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

27 DEOXYACTEIN; 6 HYDROXYCHLORZOXAZONE; ACTEIN; ALPHA HYDROXYMIDAZOLAM; BERBERINE; CAFFEINE; CHLORZOXAZONE; CIMICIFUGA RACEMOSA EXTRACT; CIMIRACEMOSIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEBRISOQUINE; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; HYDRASTINE; IBUPROFEN; KAVA EXTRACT; KAWAIN; METHYSTICIN; MIDAZOLAM; NORYANGONIN; PARAXANTHINE; PLANT EXTRACT; UNCLASSIFIED DRUG; VALERENIC ACID; VALERIAN; YANGONIN; KAVA; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG DETERMINATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEADACHE; HUMAN; HYDRASTIS EXTRACT; LIVER TOXICITY; LOW BACK PAIN; MALE; NAUSEA; NIGHTMARE; NORMAL HUMAN; PHENOTYPE; PHYTOCHEMISTRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUPPLEMENTATION; CHEMISTRY; CIMICIFUGA; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DRUG ADMINISTRATION; GENETICS; HERB DRUG INTERACTION; HYDRASTIS; METABOLISM; MICROCAPSULE; PATIENT SELECTION; PHYSIOLOGY; TIME;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CAPSULES; CIMICIFUGA; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; HYDRASTIS; KAVA; MALE; MIDAZOLAM; PATIENT SELECTION; PHENOTYPE; TIME FACTORS; VALERIAN;

EID: 19144363905     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.01.009     Document Type: Article

References (62)

1. A.A. Izzo, E. Ernst Interactions between herbal medicines and prescribed drugs a systematic review Drugs 61 2001 2163 2175
2. M.K. Ang-Lee, J. Moss, C. Yuan Herbal medicines and perioperative care JAMA 286 2001 208 216
3. N.C. Brazier, M.A.H. Levine Drug-herb interaction among commonly used conventional medicines a compendium for health care professionals Am J Ther 10 2003 163 169
4. B.J. Gurley, D.W. Hagan Herbal and dietary supplement interactions with drugs B.J. McCabe E.H. Frankel J.J. Wolfe Handbook of food-drug interactions 2003 CRC Press Boca Raton 259 293
5. G.W. Barone, B.J. Gurley, B.L. Ketel, S.R. Abul-Ezz Herbal dietary supplements a source for drug interactions in transplant recipients Transplantation 71 2001 239 241
6. S.C. Piscitelli, A.H. Burstein, D. Chaitt, R.M. Alfaro, J. Falloon Indinavir concentrations and St John's wort Lancet 355 2000 547 548
7. Z. Wang, J.C. Gorski, M.A. Hamman, S. Huang, L.J. Lesko, S.D. Hall The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin Pharmacol Ther 70 2001 317 326
8. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin Clin Pharmacol Ther 70 2001 518 524
9. R.H.J. Mathijssen, J. Verweij, P. de Bruijn, W.J. Loos, A. Sparreboom Effects of St John's wort on irinotecan metabolism J Natl Cancer Inst 94 2002 1247 1249
10. S.D. Hall, Z. Wang, S.-M. Huang, M.A. Hamman, N. Vasavada, A.Q. Adigun The interaction between St John's wort and an oral contraceptive Clin Pharmacol Ther 74 2003 525 535
11. L.B. Moore, B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, T.M. Willson St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc Natl Acad Sci U S A 97 2000 7500 7502
12. J.W. Budzinski, B.C. Foster, S. Vandenhoek, J.T. Arnason An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures Phytomedicine 7 2000 273 282
13. L. Zou, M.R. Harkey, G.L. Henderson Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity Life Sci 71 2002 1579 1589
14. B.C. Foster, S. Vandenhoek, J. Hana, A. Krantis, M.H. Akhtar, M. Bryan In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products Phytomedicine 10 2003 334 342
15. J.L. Raucy Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products Drug Metab Dispos 31 2003 533 539
16. J. Strandell, A. Neil, G. Carlin An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies Phytomedicine 11 2004 98 104
17. B.C. Foster, M.S. Foster, S. Vandenhoek, A. Krantis, J.W. Budzinski, J.T. Arnason An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic J Pharm Pharm Sci 4 2001 176 184
18. M. Unger, U. Holzgrabe, W. Jacobsen, C. Cummins, L.Z. Benet Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava kava) Planta Med 68 2002 1055 1058
19. J.M. Mathews, A.S. Etheridge, S.R. Black Inhibition of human cytochrome P450 activities by kava extract and kava lactones Drug Metab Dispos 30 2002 1153 1157
20. P. Chatterjee, M.R. Franklin Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components Drug Metab Dispos 31 2003 1391 1397
21. L. Zou, G.L. Henderson, M.R. Harkey, Y. Sakai, A. Li Effects of Kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes Phytomedicine 11 2004 285 294
22. J.C. Gorski, S.-M. Huang, A. Pinto, M.A. Hamman, J.K. Hilligoss, N.A. Zaheer The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo Clin Pharmacol Ther 75 2004 89 100
23. B.J. Gurley, S.F. Gardner, M.A. Hubbard, K. Williams, B. Gentry, J. Carrier In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto Clin Pharmacol Ther 76 2004 428 440
24. J.S. Markowitz, J.L. Donovan, C.L. DeVane, R.M. Taylor, Y. Ruan, J.-S. Wang Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers Clin Pharmacol Ther 74 2003 536 542
25. B.J. Gurley, S.F. Gardner, M.A. Hubbard, D.K. Williams, W.B. Gentry, Y. Cui Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans Clin Pharmacol Ther 72 2002 276 282
26. G.D. Anderson, G. Rosito, M.A. Mohustsy, G.W. Elmer Drug interaction potential of soy extract and Panax ginseng J Clin Pharmacol 43 2003 643 648
27. G.L. Henderson, M.R. Harkey, M.E. Gershwin, R.M. Hackman, J.S. Stern, D.M. Stresser Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity Life Sci 65 1999 209 214
28. C. Sridar, T.C. Goosen, U.M. Kent, J.A. Williams, P.F. Hollenberg Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases Drug Metab Dispos 32 2004 587 594
29. R. Venkataramanan, V. Ramachandran, B.J. Komoroski, S. Zhang, P.L. Schiff, S.C. Strom Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures Drug Metab Dispos 28 2000 1270 1273
30. J.S. Markowitz, J.L. Donovan, C.L. DeVane, L. Sipkes, K.D. Chavin Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers J Clin Psychopharmacol 23 2003 576 581
31. S.C. Piscitelli, A.H. Burstein, N. Welden, K.D. Gallicano, J. Falloon The effect of garlic supplements on the pharmacokinetics of saquinavir Clin Infect Dis 34 2002 234 238
32. J.S. Markowitz, C.L. DeVane, K.D. Chavin, R.M. Taylor, Y. Ruan, J.L. Donovan Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers Clin Pharmacol Ther 74 2003 170 177
33. J.L. Donovan, C.L. DeVane, K.D. Chavin, J.S. Wang, B.B. Gibson, H.A. Gefroh Multiple nighttime doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers Drug Metab Dispos 32 2004 1333 1336
34. C.S. Cote, C. Kor, J. Cohen, K. Auclair Composition and biological activity of traditional and commercial kava extracts Biochem Biophys Res Commun 322 2004 147 152
35. T. Lefebvre, B.C. Foster In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4 J Pharm Pharm Sci 7 2004 265 273
36. S. Russman, A. Helbling Kava hepatoxicity Ann Intern Med 135 2001 68 69
37. P.A. Whitton, A. Lau, A. Salisbury, J. Whitehouse, C.S. Evans Kava lactones and the kava-kava controversy Phytochemistry 64 2003 673 679
38. A.R. Clough, R.S. Bailie, B. Currie Liver function test abnormalities in users of aqueous kava extracts J Toxicol Clin Toxicol 41 2003 821 829
39. J.L. Palmer, R.J. Scott, A. Gibson, M. Dickins, S. Pleasance An interaction between cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A) Br J Clin Pharmacol 52 2001 555 561
40. D.T. Holland, K.A. Godfredsen, T. Page, J.D. Connor Simple high performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation J Chromatogr B Biomed Sci Appl 707 1998 105 110
41. R.F. Frye, D.D. Stiff Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography J Chromatogr B Biomed Appl 686 1996 291 296
42. R.F. Frye, R.A. Branch Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquin in human urine following direct injection J Chromatogr B Biomed Appl 677 1996 178 182
43. V. Sautou, J. Chopineau, M.P. Terrisse, P. Bastide Solid-phase extraction of midazolam and two of its metabolites from plasma for high performance liquid chromatographic analysis J Chromatogr 571 1991 298 304
44. E.A. Abourashed, I.A. Khan High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal J Pharm Sci 90 2001 817 822
45. M. Ganzera, I.A. Khan Analytical techniques for the determination of lactones in Piper methysticum Forst Chromatographia 50 1999 649 653
46. M. Ganzera, E. Bedir, I.A. Khan Separation of Cimicifuga racemosa triterpene glycosides by evaporative light scattering detection Chromatographia 52 2000 301 304
47. J.R. Mikell, M. Ganzera, I.A. Khan Analysis of sesquiterpenes in Valeriana officinalis by capillary electrophoresis Pharmazie 56 2001 946 948
48. Disintegration and dissolution of dietary supplements. In: United States Pharmacopeia and National Formulary, 27th revision. 22nd ed. Rockville (MD): United States Pharmacopeial Convention, Inc; 2004. p. 2645-6.
49. J. Cohen Statistical power analysis for the behavioral sciences 2nd ed 1988 Lawrence Erlbaum Associates Publishers Hillsdale (NJ) p. 19-42
50. M.B. Bhide, S.R. Chavan, N.K. Dutta Absorption, distribution and excretion of berberine Indian J Med Res 57 1969 2128 2131
51. G. Pan, G.J. Wang, X.D. Liu, J.P. Fawcett, Y.Y. Xie The involvement of P-glycoprotein in berberine absorption Pharmacol Toxicol 91 2002 193 197
52. R.S. Sandhu, R.P. Prescilla, T.M. Simonelli, D.J. Edwards Influence of goldenseal root on the pharmacokinetics of indinavir J Clin Pharmacol 43 2003 1283 1288
53. Y. Shao, A. Harris, M. Wang, H. Zhang, G.A. Cordell, M. Bowman, E. Lemmo Triterpene glycosides from cimicifuga racemosa J Nat Prod 63 2000 905 910
54. W. Li, Y. Sun, W. Liang, J.F. Fitzloff, R.B. van Breemen Identification of caffeic acid derivatives in Aceta racemosa (Cimicifuga racemosa, black cohosh) by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom 17 2003 978 982
55. B.M. Johnson, R.B. van Breemen In vitro formation of quinoid metabolites of the dietary supplement Cimicifuga racemosa (Black cohosh) Chem Res Toxicol 16 2003 838 846
56. A. Huntley, E. Ernst A systematic review of the safety of black cohosh Menopause 10 2003 58 64
57. F. Borrelli, A.A. Izzo, E. Ernst Pharmacological effects of Cimicifuga racemosa Life Sci 73 2003 1215 1229
58. R. Teschke, W. Gaus, D. Loew Kava extracts safety and risks including rare hepatoxicity Phytomedicine 10 2003 440 446
59. A. Avdeef, M. Strafford, E. Block, M.P. Balogh, W. Chambliss, I. Khan Drug absorption in vitro model: filter-immobilized artificial membranes 2. Studies of the permeability properties of lactones in Piper methysticum Forst Eur J Pharm Sci 14 2001 271 280
60. D.L. Clouatre Kava kava examining new reports of toxicity Toxicol Lett 150 2004 85 96
61. Food and Drug Administration (US). Kava-containing dietary supplements may be associated with severe liver injury. Advisory: Center for Food Safety and Applied Nutrition. Rockville (MD): Dept. of Health and Human Services (US). May/June 2002;36:4. Available from: URL: http://www.cfsan.fda.gov/∼dms/ addskava.html. Accessed Nov 29, 2004.
62. D. Shohet, R.B.H. Wills, D.L. Stuart Valepotriates and valerenic acid in commercial preparations of valerian available in Australia Pharmazie 56 2001 860 863